Literature DB >> 15190509

Targeting the bone marrow microenvironment in hematologic malignancies.

William S Dalton1, Lori Hazlehurst, Kenneth Shain, Terry Landowski, Melissa Alsina.   

Abstract

Unicellular drug-resistant models have been critical in elucidating intrinsic drug-resistant mechanisms; however, these models do not consider resistance mechanisms that may be elicited by extrinsic influences such as the tumor microenvironment. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumor cells to evade or circumvent drug-induced death and that this may represent a form of de novo drug resistance. We have found that elements of the bone marrow microenvironment, including extracellular matrices and normal stromal elements, protect malignant cells, including leukemia and myeloma cells, from drug-induced cell death. This extrinsic form of drug resistance may allow cells to survive initial drug treatment and thereby acquire a more complex, intrinsic drug-resistant phenotype. Focusing on this form of de novo drug resistance may ultimately prevent the emergence of acquired drug resistance and enhance drug therapy for hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15190509     DOI: 10.1053/j.seminhematol.2004.02.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  16 in total

1.  Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Authors:  Taiga Nishihori; Todd J Alekshun; Kenneth Shain; Daniel M Sullivan; Rachid Baz; Lia Perez; Joseph Pidala; Mohamed A Kharfan-Dabaja; Jose L Ochoa-Bayona; Hugo F Fernandez; Danielle N Yarde; Vasco Oliveira; William Fulp; Gang Han; Jongphil Kim; Dung-Tsa Chen; Jyoti Raychaudhuri; William Dalton; Claudio Anasetti; Melissa Alsina
Journal:  Br J Haematol       Date:  2012-03-26       Impact factor: 6.998

2.  Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a.

Authors:  Tint Lwin; Jianhong Lin; Yong Sung Choi; Xinwei Zhang; Lynn C Moscinski; Kenneth L Wright; Eduardo M Sotomayor; William S Dalton; Jianguo Tao
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

3.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

4.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

5.  Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.

Authors:  Bart Burington; Bart Barlogie; Fenghuang Zhan; John Crowley; John D Shaughnessy
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

6.  Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells.

Authors:  Tatiana M Garcia-Bates; Steven H Bernstein; Richard P Phipps
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

7.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Authors:  Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

8.  Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.

Authors:  Jaehyup Kim; Ryan A Denu; Bridget A Dollar; Leah E Escalante; Justin P Kuether; Natalie S Callander; Fotis Asimakopoulos; Peiman Hematti
Journal:  Br J Haematol       Date:  2012-05-15       Impact factor: 6.998

Review 9.  Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.

Authors:  Wei-Chih Chen; Gangqing Hu; Lori A Hazlehurst
Journal:  Curr Opin Pharmacol       Date:  2020-09-06       Impact factor: 5.547

10.  Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Tara M Tancred; Andrew R Belch; Tony Reiman; Linda M Pilarski; Julia Kirshner
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.